ACADIA Pharmaceuticals Inc. (ACAD)
How ACAD actually reacts to news — the realized, point-in-time move the market made, measured across 398 labeled events over the last three years with zero look-ahead.
ACAD’s median reaction, across the day.
Half of all ACADIA Pharmaceuticals Inc. news events land between -1.03% and +0.75% at 30 minutes.
Reaction stats as of 2026-08-13. Reaction = percent move vs. the price at the news timestamp.
Email me when ACAD moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ACAD’s baseline. Nothing else.
Get “How ACAD reacts to news” as a PDF.
A free one-page summary: ACAD’s median reaction to news and the full breakdown by event type — the numbers on this page, in one page.
Recent ACAD events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 10-Q ACADIA PHARMACEUTICALS For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.38% | +2.86% | |
| Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results | Press release | Business Wire | +3.38% | +2.86% | |
| Form 8-K ACADIA PHARMACEUTICALS For: Aug 04 | SEC filing · Form 8-K | SEC EDGAR | +3.38% | +2.86% | |
| Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference | Press release | Business Wire | -1.89% | -2.16% | |
| Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis | Press release | Business Wire | -1.11% | -3.76% | |
| Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026 | Press release | Business Wire | -0.14% | -1.42% | |
| Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer | Press release | Business Wire | +0.45% | -0.12% | |
| DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP | Press release | Business Wire | +1.27% | -2.16% | |
| Form S-8 ACADIA PHARMACEUTICALS | SEC filing · Form S-8 | SEC EDGAR | -0.43% | +1.28% | |
| Form 8-K ACADIA PHARMACEUTICALS For: May 29 | SEC filing · Form 8-K | SEC EDGAR | -0.89% | +0.56% | |
| Form 10-Q ACADIA PHARMACEUTICALS For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.46% | +3.06% | |
| Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance | Press release | Business Wire | +1.46% | +3.06% | |
| Form 8-K ACADIA PHARMACEUTICALS For: May 06 | SEC filing · Form 8-K | SEC EDGAR | +1.46% | +3.06% | |
| Form 8-K ACADIA PHARMACEUTICALS For: Apr 27 | SEC filing · Form 8-K | SEC EDGAR | -0.45% | -1.61% | |
| Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career | Press release | Business Wire | -0.45% | -1.61% | |
| Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences | Press release | Business Wire | +0.71% | -0.72% | |
| Form ARS ACADIA PHARMACEUTICALS For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.95% | -0.32% | |
| Form DEF 14A ACADIA PHARMACEUTICALS For: May 29 | SEC filing · Form DEF | SEC EDGAR | -0.95% | -0.32% | |
| Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting | Press release | Business Wire | +1.42% | +1.47% | |
| Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026 | Press release | Business Wire | -0.62% | -2.79% | |
| Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome | Press release | Business Wire | -0.41% | -0.36% | |
| Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum | Press release | Business Wire | +0.12% | -3.74% | |
| Form 8-K ACADIA PHARMACEUTICALS For: Mar 03 | SEC filing · Form 8-K | SEC EDGAR | -0.81% | -2.06% | |
| Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors | Press release | Business Wire | -1.74% | +1.48% | |
| Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome | Press release | Business Wire | +0.13% | +0.72% | |
| Form 10-K ACADIA PHARMACEUTICALS For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +2.23% | +5.62% | |
| Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview | Press release | Business Wire | +2.23% | +5.62% | |
| Form 8-K ACADIA PHARMACEUTICALS For: Feb 25 | SEC filing · Form 8-K | SEC EDGAR | +2.23% | +5.62% | |
| Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences | Press release | Business Wire | +0.32% | -1.80% | |
| Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 | Press release | Business Wire | -0.20% | -4.25% | |
| Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union | Press release | Business Wire | +0.76% | -3.62% | |
| Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference | Press release | Business Wire | -0.72% | -1.85% | |
| Form 8-K ACADIA PHARMACEUTICALS For: Jan 13 | SEC filing · Form 8-K | SEC EDGAR | -0.06% | -0.06% | |
| Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 | Press release | Business Wire | +0.04% | +1.30% | |
| Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome | Press release | Business Wire | -0.23% | +1.50% | |
| Acadia Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference | Press release | Business Wire | -0.65% | +2.26% | |
| Form 10-Q ACADIA PHARMACEUTICALS For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -7.44% | -8.19% | |
| Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview | Press release | Business Wire | -7.44% | -8.19% | |
| Form 8-K ACADIA PHARMACEUTICALS For: Nov 05 | SEC filing · Form 8-K | SEC EDGAR | -7.44% | -8.19% | |
| Form 8-K ACADIA PHARMACEUTICALS For: Oct 28 | SEC filing · Form 8-K | SEC EDGAR | -0.09% | -0.59% | |
| Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences | Press release | Business Wire | -0.58% | -0.09% | |
| Halper Sadeh LLC Encourages Acadia Pharmaceuticals Inc. Shareholders to Contact the Firm to Discuss Their Rights | Press release | Business Wire | -0.05% | +0.30% | |
| Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions | Press release | PR Newswire | -0.76% | +0.61% | |
| Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025 | Press release | Business Wire | +0.41% | -5.37% | |
| Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson’s Disease and Movement Disorders® | Press release | Business Wire | +0.19% | +0.85% | |
| Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint | Press release | Business Wire | -0.68% | +2.46% | |
| Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology | Press release | Business Wire | +0.63% | +4.31% | |
| Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +0.78% | -2.74% | |
| Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences | Press release | Business Wire | +0.27% | +2.90% | |
| Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer | Press release | Business Wire | +0.41% | +1.58% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ACAD section they belong to.
More of the dataset.
ACAD earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is ACADIA Pharmaceuticals Inc.'s median reaction calculated?
Every labeled ACAD news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 398 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 43% of ACAD's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-08-13.
Does ACAD's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.